Biomerica Advances IBS Treatment With InFoods Product, Expands Physician Network Nationwide
Biomerica Advances IBS Treatment With InFoods Product, Expands Physician Network Nationwide
Biomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products is pleased to announce advancements in the roll out of the inFoods IBS product.
全球先進醫療產品提供商Biomerica, Inc.（納斯達克股票代碼：BMRA）（“公司”）很高興地宣佈InFoods IBS產品的推出取得了進展。
Expansion Into New Offices and Physician Engagement:
Biomerica has expanded its reach with adoption by new offices in targeted regions, including the Southeast, Northeast and Midwest. The Company's new salesforce has activated over 30 new Gastrointestinal (GI) physician groups, each with multiple GI physicians, and these new practices have begun recommending the Company's revolutionary inFoods IBS Product to their IBS patients. Furthermore, the average increase in the number of physicians prescribing inFoods more than doubled each quarter over the past 12 months, reflecting growing adoption and trust within the GI medical community.
擴展到新辦公室和醫生參與：
Biomerica擴大了業務範圍，在目標地區（包括東南部、東北部和中西部）採用了新的辦事處。該公司的新銷售隊伍已經啓動了30多個新的胃腸道（GI）醫生小組，每個小組都有多名胃腸道醫生，這些新診所已開始向他們的腸易激綜合徵患者推薦該公司革命性的InFoods IBS產品。此外，在過去的12個月中，開InFoods處方的醫生人數平均每季度增長一倍以上，這反映了胃腸道醫學界的採用率和信任度的提高。
The Company is also in discussions with large non-GI physician groups for utilization of the inFoods IBS test. This advances the strategic effort to expand to non-GI physicians to provide cutting-edge non-pharmaceutical care options for individuals grappling with chronic IBS conditions.
該公司還在與大型非胃腸道醫生團體討論使用InFoods腸易激綜合徵測試的問題。這推動了向非胃腸易激綜合徵醫生擴展的戰略努力，爲患有慢性腸易激綜合徵疾病的個人提供尖端的非藥物護理選擇。
This continued expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for irritable bowel syndrome (IBS) while positioning the Company for product revenue growth over the coming quarters.
這種持續擴張表明，InFoods IBS測試在醫學界越來越受到認可和採用，擴大了Biomerica在爲腸易激綜合症（IBS）提供創新解決方案方面的影響力，同時爲公司未來幾個季度的產品收入增長做好了準備。